Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Intas Pharmaceuticals Ltd. maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 2 pending office actions currently active. These actions are split between 2 distinct examiners, each managing 1 pending matter. This distribution indicates that the company is engaging with multiple reviewers for its pharmaceutical filings. The presence of 2 pending office actions suggests a focused prosecution phase within the biotechnology sector.
The prosecution is concentrated within 1 distinct art unit, suggesting a very specific technical focus for the pending applications. ROSSI, JULIA ANNE LORRAIN is the busiest examiner with 1 pending office action. The use of 2 distinct examiners within a single art unit provides a narrow but shared jurisdictional footprint at the patent office. For a practitioner, this means that while the 2 pending office actions are being reviewed by 2 distinct examiners, they are both subject to the technical standards of the same art unit. This concentration allows for a more unified technical strategy even when dealing with 2 distinct examiners for the 2 pending actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROSSI, JULIA ANNE LORRAIN | 1 | 45.7% | +61.3% |
| LIU, TRACY | 1 | 54.5% | +27.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18854146 | AN ORODISPERSIBLE TABLET OF RIVAROXABAN | ROSSI, JULIA ANNE LORRAIN | — |
| 17631676 | PHARMACEUTICAL COMPOSITION COMPRISING HMG-COA REDUCTASE INHIBITORS AND FENOFIBRATE | LIU, TRACY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18854146 | AN ORODISPERSIBLE TABLET OF RIVAROXABAN | ROSSI, JULIA ANNE LORRAIN | — |
| 17631676 | PHARMACEUTICAL COMPOSITION COMPRISING HMG-COA REDUCTASE INHIBITORS AND FENOFIBRATE | LIU, TRACY | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18854146 | AN ORODISPERSIBLE TABLET OF RIVAROXABAN | ROSSI, JULIA ANNE LORRAIN | — | §103§112 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 17631676 | PHARMACEUTICAL COMPOSITION COMPRISING HMG-COA REDUCTASE INHIBITORS AND FENOFIBRATE | LIU, TRACY | 1614 | §103§112 | Final Rejection | — | Pending | Jan 31, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial